A pilot study of the pan-class I PI3K inhibitor buparlisib in combination with cetuximab in patients with recurrent or metastatic head and neck cancer.

Ryan J BrissonSara KochannySaba ArshadAllison DekkerJonas A DeSouzaVassiliki SalouraEverett E VokesTanguy Y Seiwert

Published in: Head & neck (2019)

Based on this pilot study, buparlisib at 100 mg daily plus cetuximab proved to be well-tolerated. Patients previously treated with cetuximab monotherapy showed benefit from this combination.

Keyphrases

end stage renal disease
metastatic colorectal cancer
newly diagnosed
locally advanced
squamous cell carcinoma
ejection fraction
small cell lung cancer
chronic kidney disease
wild type
peritoneal dialysis
physical activity
prognostic factors
clinical trial
patient reported outcomes
rectal cancer
patient reported